The antibiotic development and commercialization system fails to deliver needed treatments
#00372
Scientific risk, weak commercial returns and unequal market access leave too few innovative antibiotics for priority resistant pathogens and limit delivery after approval.
#00392Fund priority antibacterial products through milestone-based public and nonprofit programmes
Provide grants and milestone payments for high-priority antibiotics, diagnostics and nontraditional products while attaching stewardship, access and data-sharing conditions.
#00394Standardize matched bacteriophage therapy and quality-controlled manufacturing
Develop regulated phage libraries, rapid bacterial matching, stable manufacturing, and adaptive treatment protocols for infections that lack effective antibiotic options.
#00391Delink antibiotic revenue from sales volume through subscription payments
Pay suppliers predictable amounts for the availability and public-health value of priority antibiotics rather than rewarding the number of doses sold.
#00393Develop new antibiotic classes with equitable-access conditions
Prioritize antibiotics with new targets or mechanisms against critical resistant pathogens and plan registration, manufacturing, supply and stewardship across income settings before approval.